Skip to content

Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults

Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00890149
Enrollment
74
Registered
2009-04-29
Start date
2015-09-30
Completion date
2017-03-31
Last updated
2023-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Abuse, Alcoholism

Keywords

alcohol abuse, binge drinking, severe drinking, alcoholism, heavy drinking

Brief summary

This study will evaluate the efficacy of ondansetron + BASICS Plus in reducing severe or binge drinking among emerging adults. BASIC Plus (Brief Alcohol Screening and Intervention for College Students) has been the most validated brief intervention among college students. The BASICS program provides personal feedback, motivation, and strategies that enhance normative drinking patterns

Detailed description

We propose to conduct a 9 week study to test the efficacy of ondansetron in a heavy drinking (non-dependent) emerging adult population. We will enroll individuals between the ages of 18 and 25 years as this period overlaps with the general population of those attending college and who can be defined as emerging adults. We will conduct a double-blind control study in which 150 individuals will be randomized into 2 groups, therefore the N will be 300.

Interventions

DRUGOndansetron

Ondansetron (4ug/kg bid),

DRUGPlacebo

Placebo bid

BEHAVIORALBASICS Plus

Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
University of Maryland, Baltimore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* White Males and females who have given written informed consent. * Ages 18 through 25;also, patients must weigh ≥40 kg and ≤140 kg. * Good physical health as determined by a complete physical examination, an EKG within normal limits, and laboratory screening tests within acceptable parameters. * At least an average of one episode of binge or heavy drinking per week in the past month prior to enrollment. For men and women, that is ≥5 and ≥4 drinks/drinking day, respectively.They also need to report at least one day of heavy drinking within the 7 days prior to randomization. * The pregnancy test for females at intake must be negative. Additionally, women of childbearing potential must be using an acceptable form of contraception. * Literate in English and able to read, understand, and complete the rating scales and questionnaires accurately, follow instructions, and make use of the behavioral treatments. * Answer an advertisement in the newspaper/radio/television, and express a wish to stop heavy drinking. * Willingness to participate in behavioral treatments to stop heavy drinking

Exclusion criteria

Please contact site for additional information

Design outcomes

Primary

MeasureTime frameDescription
Ondansetron + BASICS Plus shall be more effective at reducing severe or binge drinking among emerging adults. The treatment effect of ondansetron on reduction in severe or binge drinking shall be greatest in LL individuals.Throughout the studySelf-report use, Timeline Follow-back, daily drinking questionnaires, Rutgers Alcohol Problem Index, Genotyping

Secondary

MeasureTime frameDescription
Ondansetron adds to the therapeutic benefit of BASICS Plus, even in those with lower readiness for changeThroughout the studyICR Scale to abstain from using alcohol, ICR Scale for medication adherence, medication compliance,craving assessments

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026